期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

福善美的循证医学证据解读 被引量：1

原文传递
导出
摘要 福善美作为抗骨质疏松的一线药物在临床得到广泛应用，其疗效也得到临床医生的肯定。但随着医学模式的转变，以往以个人用药经验或上级医生观点，或根据病例报道归纳的结论作为治疗决策依据的传统医学模式已逐渐被循证医学模式所取代。福善美在循证医学模式下的表现如何，是否与医生在临床实践中所得到的结论相符，正是总结这篇综述的初衷。
作者 戴晨琳 朱梅
机构地区 天津医科大学总医院内分泌科
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2012年第10期923-926,共4页 Chinese Journal of Geriatrics
关键词 循证医学模式 福善美 证据解读 临床医生 抗骨质疏松 一线药物 用药经验 病例报道
分类号 R580 [医药卫生—内分泌]
  • 相关文献

参考文献30

  • 1Black DM,felsenberg D, Hanley DA, et al. Fracture risk reduction with alendronate in women with osteoporosis the fracture intervention trial. J Clin Endocrinol Metab, 2000, 85:4118-4124.
  • 2Black DM, Cummings SR, Karph DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet, 1996, 348 : 1535-1541.
  • 3Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low hone density but without vertebral fractures: results from the fracture intervention trial. JAMA, 1998, 280:2077-2082.
  • 4Sxhwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX Trial. J Bone Miner Res, 2010, 25: 976-982.
  • 5Papapoulos SE, Quandt SA, Liberman UAT, et al. Meta analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int, 2005, 16:468-474.
  • 6Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev, 2008, 1 :CD001155.
  • 7袁霆,李晓林,张长青,施慧鹏,曾炳芳.阿伦膦酸钠防止绝经后妇女髋部骨折的荟萃分析[J].中华医学杂志,2009,89(23):1620-1622. 被引量：2
  • 8Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax international trial study group. Osteoporos Int, 1999, 9: 461-468.
  • 9Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med, 2004,350: 1189-1199.
  • 10Cranney A, Well G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Reviews, 2002, 23:508-516.

二级参考文献45

  • 1吴智鸿,赵水平.他汀类药物抗骨质疏松作用的研究进展[J].中华老年医学杂志,2005,24(1):64-66. 被引量：11
  • 2蒋朱明,江华.谷氨酰胺双肽对手术后患者结局影响的临床随机对照研究荟萃分析[J].中华医学杂志,2006,86(23):1610-1614. 被引量：36
  • 3王洪复.老年人骨质疏松的诊断与筛查[J].中华老年医学杂志,2006,25(6):407-409. 被引量：21
  • 4Wells GA,Cranney A,Peterson J,et al.Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopansal women.Cochrane Database Syst Rey,2008:CD001155.
  • 5Brown JP,Josse RG.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.CMAJ,2002,167:1-34.
  • 6Cummings SR,Melton LJ.Epidemiology and outcomes of osteoporotic fractures.Lancet,2002,359:1761-1767.
  • 7Black DM,Cummings SR,Karpf DB,et al.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.Lancet,1996,348:1535-1541.
  • 8Black DM,Thompson DE,Bauer DC,et al.Fracture risk reduction with alendronate in women with osteoporosis:the fracture intervention trial.J Clin Endocrinol Metab,2000,85:4118-4124.
  • 9Papapoulos SE,Quandt SA,Liberman UA,et al.Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopansal women.Osteopores Int,2005,16:468-474.
  • 10Sato Y,Iwamoto J,Kanoko T,et al.Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease:a randomized controllad trial.Mov Disord,2006,21:924-929.

共引文献4

同被引文献9

  • 1吴宜勇.绝经后骨质疏松的判断和处理[J].中华全科医师杂志,2004,3(5):287-288. 被引量：2
  • 2Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form HealthSurvey : construction of scales and preliminary tests of reliabilityand validity[ J]. Med Care,1996,34(3) :220-233.
  • 3Drake MT, Clarke BL, Lewiecki EM. The pathophysiology andtreatment of osteoporosis[ J]. Clin Ther,2015 ,37(8) : 1837-1850.
  • 4Chesnut CR, Azria M,Silverman S, et al. Salmon calcitonin: areview of current and future therapeutic indications [ J ].Osteoporos Int, 2008 , 19 (4) : 479-491.
  • 5Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosisand bone pain [ J]. Cuit Pharm Des,2003 ,9 ( 32 ) : 2659-2676.
  • 6Karponis A, Rizou S, Pallis D, et al. Analgesic effect of nasalsalmon calcitonin during the early post-fracture period of the distalradius fracture [ J ]. J Musculoskelet Neuronal Interact,2015,15(2) :186-189.
  • 7Maraka S, Kennel KA. Bisphosphonates for the prevention andtreatment of osteoporosis[ J] . BMJ,2015,351 : h3783.
  • 8Greenspan S L,Perera S, Ferchak MA, et al. Efficacy and safetyof single-dose zoledronic acid for osteoporosis in frail elderlywomen: a randomized clinical trial[ J]. JAMA Intern Med,2015 ,175(6) :913-921.
  • 9Sunyecz JA. Zoledronic acid infusion for prevention and treatmentof osteoporosis[ J]. Int J Womens Health,2010,2:353-360.

引证文献1

二级引证文献33

中华老年医学杂志
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部